Dean Falb

Dean Falb has an extensive work experience in the biotechnology and pharmaceutical industry. Dean is currently serving as the Chief Scientific Officer at Frontera Therapeutics since May 2022. In addition, they are a Scientific Advisory Board Member at Novome Biotechnologies. Previously, Dean held the position of Chief Scientific Officer at PlateletBio from January 2020 to the present. Prior to that, they worked as the CSO at LogicBio Therapeutics from 2018 to 2020. Dean also served as a Student Advisor at Harvard i-lab from 2014 to 2020. Dean has a strong background in synthetic biology as the Founder and CTO of Synlogic, Inc. from 2013 to 2018. Dean has also held positions at Atlas Ventures, Stryker Regenerative Medicine, Neogenesis (Merck), and Praecis Pharmaceuticals (GSK).

Dean Falb earned a Ph.D. in Biochemistry and Molecular Biology from Harvard University. Prior to that, they obtained a B.S. in Chemistry from Purdue University. Additionally, Dean completed the Executive Leadership Program at Harvard Business School.